CA2205112C - Methode et composition de traitement de maladies mammaliennes provoquees par une reaction inflammatoire - Google Patents

Methode et composition de traitement de maladies mammaliennes provoquees par une reaction inflammatoire Download PDF

Info

Publication number
CA2205112C
CA2205112C CA002205112A CA2205112A CA2205112C CA 2205112 C CA2205112 C CA 2205112C CA 002205112 A CA002205112 A CA 002205112A CA 2205112 A CA2205112 A CA 2205112A CA 2205112 C CA2205112 C CA 2205112C
Authority
CA
Canada
Prior art keywords
pyruvate
respiratory disease
inflammatory mediator
pharmaceutical composition
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002205112A
Other languages
English (en)
Other versions
CA2205112A1 (fr
Inventor
Stanley E. Katz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cellular Sciences Inc
Original Assignee
Cellular Sciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellular Sciences Inc filed Critical Cellular Sciences Inc
Publication of CA2205112A1 publication Critical patent/CA2205112A1/fr
Application granted granted Critical
Publication of CA2205112C publication Critical patent/CA2205112C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

L'invention porte sur une méthode de traitement d'un état pathologique chez des mammifères provoqué par des cellules mammaliennes impliquées dans une réaction inflammatoire. On met ces cellules mammaliennes participant à la réaction inflammatoire en contact avec un médiateur de la réaction inflammatoire, ce qui permet d'atténuer la réaction inflammatoire indésirable, ce médiateur étant un antioxydant. Ce médiateur de la réaction inflammatoire peut également fournir une source d'énergie cellulaire et constituer un bloc de construction dans la synthèse cellulaire d'autres composantes cellulaires. L'invention a également trait à des compositions visant à atténuer et à traiter une réaction inflammatoire indésirable.
CA002205112A 1995-09-19 1996-09-06 Methode et composition de traitement de maladies mammaliennes provoquees par une reaction inflammatoire Expired - Lifetime CA2205112C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US396295P 1995-09-19 1995-09-19
US60/003,962 1995-09-19
PCT/US1996/014304 WO1997010818A1 (fr) 1995-09-19 1996-09-06 Methode et composition de traitement de maladies mammaliennes provoquees par une reaction inflammatoire

Publications (2)

Publication Number Publication Date
CA2205112A1 CA2205112A1 (fr) 1997-03-27
CA2205112C true CA2205112C (fr) 2008-11-18

Family

ID=21708422

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002205112A Expired - Lifetime CA2205112C (fr) 1995-09-19 1996-09-06 Methode et composition de traitement de maladies mammaliennes provoquees par une reaction inflammatoire

Country Status (10)

Country Link
EP (1) EP0804181A4 (fr)
JP (1) JP4459303B2 (fr)
AU (1) AU719332B2 (fr)
CA (1) CA2205112C (fr)
IL (1) IL119225A (fr)
MX (1) MX9703653A (fr)
NZ (1) NZ306832A (fr)
TW (1) TW434012B (fr)
WO (1) WO1997010818A1 (fr)
ZA (1) ZA967833B (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60045445D1 (de) * 1999-05-14 2011-02-10 Cellular Sciences Inc Verfahren und zusammensetzung zur behandlung von entzündungsreaktion bedingten nasen- und nebenhölenkrankheiten in säugetieren
WO2002074301A1 (fr) * 2001-03-15 2002-09-26 University Of Pittsburgh Of The Commonwealth System Of Higher Education Procede d'utilisation d'un pyruvate et/ou de ses derives dans le traitement d'etats inflammatoires induits par des cytokines
US6689810B2 (en) * 2001-08-21 2004-02-10 Cellular Sciences, Inc. Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
US6623723B2 (en) * 2001-08-21 2003-09-23 Cellular Sciences Inc. Method for treating bronchial constriction and bronchospasm
US20030105162A1 (en) * 2001-08-21 2003-06-05 Celluar Sciences, Inc. Method for treating bronchial constriction and bronchospasm
US8076373B2 (en) * 2001-09-11 2011-12-13 North Cell Pharmacetical Method for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
WO2009116546A1 (fr) * 2008-03-18 2009-09-24 国立大学法人 岡山大学 Médiateur chimique excitateur et procédé de criblage associé
US11571455B2 (en) 2013-04-11 2023-02-07 Vanderbilt University Methods and compositions for treating alcoholic liver disease
WO2018232383A1 (fr) * 2017-06-16 2018-12-20 Vanderbilt University Méthodes et compositions pour le traitement d'une inflammation microbienne
EP3797766A1 (fr) * 2019-09-24 2021-03-31 Evonik Operations GmbH Compositions à utiliser pour réduire l'inflammation
EP4058556A1 (fr) * 2019-11-14 2022-09-21 Merck Patent GmbH Milieux de culture cellulaire

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1857M (fr) * 1962-03-08 1963-06-10 Roussel Uclaf Nouveau médicament notamment pour le traitement des maladies d'origine virale.
US3279997A (en) * 1963-10-22 1966-10-18 Herbert D Schneyer Enteric coated calcium lactate tablets containing an antihistamine and thiamine chloride
US3879537A (en) * 1973-09-04 1975-04-22 Scott Eugene J Van Treatment of ichthyosiform dermatoses
US3988470A (en) * 1974-02-25 1976-10-26 Scott Eugene J Van Treatment of palmar and plant disturbed keratosis
US4158057A (en) * 1975-03-28 1979-06-12 Stanko Ronald T Prevention of the accumulation of fatty deposits in the liver
US4197316A (en) * 1975-07-23 1980-04-08 Scott Eugene J Van Treatment of dry skin
US4021572A (en) * 1975-07-23 1977-05-03 Scott Eugene J Van Prophylactic and therapeutic treatment of acne vulgaris utilizing lactamides and quaternary ammonium lactates
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US4415576A (en) * 1981-04-01 1983-11-15 Montefiore Hospital Method for preventing body fat deposition in mammals
US4351835A (en) * 1981-04-01 1982-09-28 Montefiore Hospital Method for preventing body fat deposition in mammals
US4521375A (en) * 1982-11-23 1985-06-04 Coopervision, Inc. Sterilizing treatment with hydrogen peroxide and neutralization of residual amounts thereof
DE3302694A1 (de) * 1983-01-27 1984-08-02 Retheto Filmtechnik Theilemann & Co, 8000 München Mundpflegemittel
DE3586844T2 (de) * 1984-06-22 1994-03-17 Richard L Veech Elektrolytlösungen und deren (in vivo) verwendung.
US4696917A (en) * 1985-08-01 1987-09-29 Lindstrom Richard L Irrigation solution
JPS63135370A (ja) * 1986-11-26 1988-06-07 Grelan Pharmaceut Co Ltd 抗アレルギ−剤
IN168530B (fr) * 1987-11-06 1991-04-20 Lyphomed Inc
WO1990000900A1 (fr) * 1988-07-20 1990-02-08 Amgen Inc. Procede de traitement de troubles inflammatoires par reduction de l'activation phagocytaire
JP2794021B2 (ja) * 1988-11-02 1998-09-03 エーザイ株式会社 アゼラスチン或いはその塩類含有経皮適用製剤
AU7699191A (en) * 1990-03-30 1991-10-30 Amgen, Inc. Respiratory burst suppression factor
US5210098A (en) * 1990-09-21 1993-05-11 Regents Of The University Of Minnesota Use of pyruvate to treat acute renal failure
US5296370A (en) * 1990-10-04 1994-03-22 Rutgers, The State University Repair medium for the resuscitation of injured cells
US5648380A (en) * 1991-03-01 1997-07-15 Warner-Lambert Company Anti-inflammatory wound healing compositions and methods for preparing and using same
AU4275793A (en) * 1992-02-25 1993-09-13 Warner-Lambert Company Cytoprotective compositions containing pyruvate and antioxidants
US5256697A (en) * 1992-04-16 1993-10-26 Abbott Laboratories Method of administering pyruvate and methods of synthesizing pyruvate precursors
JP3236658B2 (ja) * 1992-04-27 2001-12-10 花王株式会社 気管支拡張剤
US5536751A (en) * 1994-05-09 1996-07-16 The United States Of America As Represented By The Secretary Of The Army Pharmaceutical alpha-keto carboxylic acid compositions method of making and use thereof

Also Published As

Publication number Publication date
IL119225A (en) 2000-09-28
IL119225A0 (en) 1996-12-05
EP0804181A1 (fr) 1997-11-05
AU719332B2 (en) 2000-05-04
ZA967833B (en) 1997-06-02
CA2205112A1 (fr) 1997-03-27
NZ306832A (en) 2001-04-27
JPH10509463A (ja) 1998-09-14
WO1997010818A1 (fr) 1997-03-27
TW434012B (en) 2001-05-16
EP0804181A4 (fr) 2005-02-02
MX9703653A (es) 1998-07-31
JP4459303B2 (ja) 2010-04-28
AU6915996A (en) 1997-04-09

Similar Documents

Publication Publication Date Title
US5798388A (en) Method and composition for treating mammalian diseases caused by inflammatory response
AU2006213755B2 (en) Method and composition for treating mammalian diseases and injuries caused by the over-expression of peroxynitrite
EP0792163B1 (fr) Compositions cicatrisantes et anti-acne contenant un pyruvate, un antioxydant et un melange d'acides gras
CA2457983C (fr) Methode de traitement d'etats d'une maladie pulmonaire chez des mammaliens par modification des niveaux indigenes in vivo d'oxyde nitrique
JP3506701B2 (ja) 創傷治癒組成物，その調製方法と使用
AU2002329762A1 (en) Method for treating pulmonary disease states in mammals by altering indigenous in vivo levels of nitric oxide
CA2205112C (fr) Methode et composition de traitement de maladies mammaliennes provoquees par une reaction inflammatoire
AU1328501A (en) Treatments based on discovery that nitric oxide synthase is a paraquat diaphorase
US7122578B2 (en) Method and composition for treating mammalian diseases and injuries which cause pain, erythema, swelling, crusting, ischemia scarring and excess white blood cell infiltration
AU4275793A (en) Cytoprotective compositions containing pyruvate and antioxidants
JP2011190274A (ja) 炎症反応により生ずる哺乳動物の鼻および副鼻洞の病気を処置する方法および組成物
CZ20021559A3 (cs) Použití oxidu dusnatého pro výrobu léku k léčení konstrikce dýchacích cest
AU674131C (en) Wound healing compositions containing a pyruvate, an antioxidant and a mixture of fatty acids
EP0753309A2 (fr) Composition de lactoferrine (ou de protéines analogues) et de méthanesulfonate de désferrioxamine (ou d'autres chélateurs d'ions métalliques) pour la thérapie de maladies infectieuses virales

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20160906